For example, in 2004, Lynch et al. described mutations in the epidermal growth factor receptor (EGFR) that led to FDA approval in 2013 of erlotinib and gefitinib as first-line treatments for patients with NSCLC with advanced mutated EGFR [27]. Here, EGFR is linked to non-small cell lung carcinoma.